• 12717 Citations
  • 39 h-Index
1973 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

2020

Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: Results from TExT and Soft

Pagani, O., Francis, P. A., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Pinotti, G., Di Leo, A., Coates, A. S., Goldhirsch, A., Gelber, R. D. & Regan, M. M., ápr. 20 2020, In : Journal of Clinical Oncology. 38, 12, p. 1293-1303 11 p.

Research output: Article

Open Access
6 Citations (Scopus)

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

Eiger, D., Pondé, N. F., Agbor-Tarh, D., Moreno-Aspitia, A., Piccart, M., Hilbers, F. S., Werner, O., Chumsri, S., Dueck, A., Kroep, J. R., Gomez, H., Láng, I., Rodeheffer, R. J., Ewer, M. S., Suter, T. & de Azambuja, E., máj. 12 2020, In : British journal of cancer. 122, 10, p. 1453-1460 8 p.

Research output: Article

2019

Adjuvant Anti-HER2 Therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients

Lambertini, M., Campbell, C., Bines, J., Korde, L. A., Izquierdo, M., Fumagalli, D., Del Mastro, L., Ignatiadis, M., Pritchard, K., Wolff, A. C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Barrios, C. H., Baselga, J., Moreno-Aspitia, A., Piccart, M. & 2 others, Gelber, R. D. & De Azambuja, E., jan. 1 2019, In : Journal of the National Cancer Institute. 111, 1, djy094.

Research output: Article

17 Citations (Scopus)

Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer

Huober, J., Holmes, E., Baselga, J., de Azambuja, E., Untch, M., Fumagalli, D., Sarp, S., Lang, I., Smith, I., Boyle, F., Xu, B., Lecocq, C., Wildiers, H., Jouannaud, C., Hackman, J., Dasappa, L., Ciruelos, E., Toral Pena, J. C., Adamchuk, H., Hickish, T. & 5 others, de la Pena, L., Jackisch, C., Gelber, R. D., Piccart-Gebhart, M. & Di Cosimo, S., szept. 2019, In : European Journal of Cancer. 118, p. 169-177 9 p.

Research output: Article

3 Citations (Scopus)
2018

Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the CALOR trial

Wapnir, I. L., Price, K. N., Anderson, S. J., Robidoux, A., Martín, M., Nortier, J. W. R., Paterson, A. H. G., Rimawi, M. F., Láng, I., Baena-Cañada, J. M., Thürlimann, B., Mamounas, E. P., Geyer, C. E., Gelber, S., Coates, A. S., Gelber, R. D., Rastogi, P., Regan, M. M., Wolmark, N. & Aebi, S., ápr. 10 2018, In : Journal of Clinical Oncology. 36, 11, p. 1073-1079 7 p.

Research output: Article

28 Citations (Scopus)
1 Citation (Scopus)

Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00

Munzone, E., Gray, K. P., Fumagalli, C., Guerini-Rocco, E., Láng, I., Ruhstaller, T., Gianni, L., Kammler, R., Viale, G., Di Leo, A., Coates, A. S., Gelber, R. D., Regan, M. M., Goldhirsch, A., Barberis, M. & Colleoni, M., júl. 1 2018, In : Breast Cancer Research and Treatment. 170, 2, p. 351-360 10 p.

Research output: Article

2 Citations (Scopus)

Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer

Rubovszky, G., Budai, B., Ganofszky, E., Horváth, Z., Juhos, É., Madaras, B., Nagy, T., Szabó, E., Pintér, T., Tóth, E., Nagy, P., Láng, I. & Hitre, E., ápr. 1 2018, In : Pathology and Oncology Research. 24, 2, p. 237-244 8 p.

Research output: Article

4 Citations (Scopus)
2017

Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer

Von Minckwitz, G., Procter, M., De Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., Knott, A., Lang, I., Levy, C., Yardley, D. A., Bines, J., Gelber, R. D., Piccart, M. & Baselga, J., júl. 13 2017, In : New England Journal of Medicine. 377, 2, p. 122-131 10 p.

Research output: Article

365 Citations (Scopus)

Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 study

Borgquist, S., Giobbie-Hurder, A., Ahern, T. P., Garber, J. E., Colleoni, M., Láng, I., Debled, M., Ejlertsen, B., Von Moos, R., Smith, I., Coates, A. S., Goldhirsch, A., Rabaglio, M., Price, K. N., Gelber, R. D., Regan, M. M. & Thürlimann, B., ápr. 10 2017, In : Journal of Clinical Oncology. 35, 11, p. 1179-1188 10 p.

Research output: Article

34 Citations (Scopus)

memo: Spectacular developments during the last decade from the Section Editors’ point of view

Hofer, S., Gunsilius, E., Láng, I. & Moiseyenko, V., febr. 1 2017, In : Memo - Magazine of European Medical Oncology. 10, 1, p. 4-7 4 p.

Research output: Editorial

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

On behalf of CALOR trial investigators, febr. 1 2017, In : Annals of Surgical Oncology. 24, 2, p. 398-406 9 p.

Research output: Article

12 Citations (Scopus)

predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab

Duchnowska, R., Sperinde, J., Czartoryska-Arlukowicz, B., Myśliwiec, P., Winslow, J., Radecka, B., Petropoulos, C., Demlova, R., Orlikowska, M., Kowalczyk, A., Láng, I., Ziółkowska, B., Debska-Szmich, S., Merdalska, M., Grela-Wojewoda, A., Zawrocki, A., Biernat, W., Huang, W. & Jassem, J., jan. 1 2017, In : Oncotarget. 8, 61, p. 104149-104159 11 p.

Research output: Article

7 Citations (Scopus)
2016

Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, Human epidermal growth factor receptor 2-Negative early breast cancer: TEXT and SOFT Trials

Regan, M. M., Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Pinotti, G., Price, K. N., Coates, A. S., Goldhirsch, A. & Gelber, R. D., júl. 1 2016, In : Journal of Clinical Oncology. 34, 19, p. 2221-2230 10 p.

Research output: Article

69 Citations (Scopus)

Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial

Piccart-Gebhart, M., Holmes, E., Baselga, J., De Azambuja, E., Dueck, A. C., Viale, G., Zujewski, J. A., Goldhirsch, A., Armour, A., Pritchard, K. I., McCullough, A. E., Dolci, S., McFadden, E., Holmes, A. P., Tonghua, L., Eidtmann, H., Dinh, P., Di Cosimo, S., Harbeck, N., Tjulandin, S. & 15 others, Im, Y. H., Huang, C. S., Díeras, V., Hillman, D. W., Wolff, A. C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Gomez, H., Suter, T., Gelber, R. D. & Perez, E. A., ápr. 1 2016, In : Journal of Clinical Oncology. 34, 10, p. 1034-1042 9 p.

Research output: Article

176 Citations (Scopus)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Zielinski, C., Láng, I., Inbar, M., Kahán, Z., Greil, R., Beslija, S., Stemmer, S. M., Zvirbule, Z., Steger, G. G., Melichar, B., Pienkowski, T., Sirbu, D., Petruzelka, L., Eniu, A., Nisenbaum, B., Dank, M., Anghel, R., Messinger, D. & Brodowicz, T., szept. 1 2016, In : The Lancet Oncology. 17, 9, p. 1230-1239 10 p.

Research output: Article

28 Citations (Scopus)

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: Expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

Finn, R. S., Crown, J. P., Ettl, J., Schmidt, M., Bondarenko, I. M., Láng, I., Pintér, T., Boer, K., Patel, R., Randolph, S., Kim, S. T., Huang, X., Schnell, P., Nadanaciva, S., Bartlett, C. H. & Slamon, D. J., jún. 28 2016, In : Breast Cancer Research. 18, 1, 67.

Research output: Article

74 Citations (Scopus)

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients

For the Central and East European Oncology Group (CEEOG), jan. 1 2016, In : Oncotarget. 7, 1, p. 550-564 15 p.

Research output: Article

6 Citations (Scopus)

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

Bell, T., Crown, J. P., Láng, I., Bhattacharyya, H., Zanotti, G., Randolph, S., Kim, S., Huang, X., Huang Bartlett, C., Finn, R. S. & Slamon, D., máj. 3 2016, In : Current Medical Research and Opinion. 32, 5, p. 959-965 7 p.

Research output: Article

13 Citations (Scopus)

Lapatinib-related rash and breast cancer outcome in the ALTTO phase III randomized trial

Sonnenblick, A., De Azambuja, E., Agbor-Tarh, D., Bradbury, I., Campbell, C., Huang, Y., Dueck, A. C., Pritchard, K. I., Wolff, A. C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Gomez, H., Perez, E. A., Piccart, M. & Azim, H. A., jan. 1 2016, In : Journal of the National Cancer Institute. 108, 8, djw037.

Research output: Article

14 Citations (Scopus)

Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00

Colleoni, M., Gray, K. P., Gelber, S., Láng, I., Thürlimann, B., Gianni, L., Abdi, E. A., Gomez, H. L., Linderholm, B. K., Puglisi, F., Tondini, C., Kralidis, E., Eniu, A., Cagossi, K., Rauch, D., Chirgwin, J., Gelber, R. D., Regan, M. M., Coates, A. S., Price, K. N. & 2 others, Viale, G. & Goldhirsch, A., okt. 1 2016, In : Journal of Clinical Oncology. 34, 28, p. 3400-3408 9 p.

Research output: Article

37 Citations (Scopus)

Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: Results of the CECOG LaVie trial

Thallinger, C., Lang, I., Kuhar, C. G., Bartsch, R., Singer, C. F., Petruzelka, L., Melichar, B., Knittelfelder, R., Brodowicz, T. & Zielinski, C., febr. 18 2016, In : BMC cancer. 16, 1, 121.

Research output: Article

4 Citations (Scopus)

Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer

Zielinski, C., Lang, I., Beslija, S., Kahan, Z., Inbar, M. J., Stemmer, S. M., Anghel, R., Vrbanec, D., Messinger, D. & Brodowicz, T., jan. 19 2016, In : British journal of cancer. 114, 2, p. 163-170 8 p.

Research output: Article

11 Citations (Scopus)

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

Jerusalem, G., Mariani, G., Ciruelos, E. M., Martin, M., Tjan-Heijnen, V. C. G., Neven, P., Gavila, J. G., Michelotti, A., Montemurro, F., Generali, D., Simoncini, E., Lang, I., Mardiak, J., Naume, B., Camozzi, M., Lorizzo, K., Bianchetti, S. & Conte, P., szept. 1 2016, In : Annals of Oncology. 27, 9, p. 1719-1725 7 p.

Research output: Article

22 Citations (Scopus)

Treatment adherence and its impact on Disease-Free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence

Chirgwin, J. H., Giobbie-Hurder, A., Coates, A. S., Price, K. N., Ejlertsen, B., Debled, M., Gelber, R. D., Goldhirsch, A., Smith, I., Rabaglio, M., Forbes, J. F., Neven, P., Láng, I., Colleoni, M. & Thürlimann, B., júl. 20 2016, In : Journal of Clinical Oncology. 34, 21, p. 2452-2459 8 p.

Research output: Article

70 Citations (Scopus)

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

Pruneri, G., Gray, K. P., Vingiani, A., Viale, G., Curigliano, G., Criscitiello, C., Láng, I., Ruhstaller, T., Gianni, L., Goldhirsch, A., Kammler, R., Price, K. N., Cancello, G., Munzone, E., Gelber, R. D., Regan, M. M. & Colleoni, M., júl. 1 2016, In : Breast Cancer Research and Treatment. 158, 2, p. 323-331 9 p.

Research output: Article

52 Citations (Scopus)

Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy

Bellet, M., Gray, K. P., Francis, P. A., Láng, I., Ciruelos, E., Lluch, A., Climent, M. A., Catalán, G., Avella, A., Bohn, U., González-Martin, A., Ferrer, R., Catalán, R., Azaro, A., Rajasekaran, A., Morales, J., Vázquez, J., Fleming, G. F., Price, K. N. & Regan, M. M., máj. 10 2016, In : Journal of Clinical Oncology. 34, 14, p. 1584-1593 10 p.

Research output: Article

51 Citations (Scopus)
2015

Adjuvant ovarian suppression in premenopausal breast cancer

Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., Martino, S., Davidson, N. E., Geyer, C. E., Walley, B. A., Coleman, R., Kerbrat, P., Buchholz, S., Ingle, J. N., Winer, E. P. M., Rabaglio-Poretti, M. & 9 others, Maibach, R., Ruepp, B., Giobbie-Hurder, A., Price, K. N., Colleoni, M., Viale, G., Coates, A. S., Goldhirsch, A. & Gelber, R. D., jan. 1 2015, In : New England Journal of Medicine. 372, 5, p. 436-446 11 p.

Research output: Article

321 Citations (Scopus)

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., Shparyk, Y., Thummala, A. R., Voytko, N. L., Fowst, C., Huang, X., Kim, S. T., Randolph, S. & Slamon, D. J., jan. 1 2015, In : The Lancet Oncology. 16, 1, p. 25-35 11 p.

Research output: Article

924 Citations (Scopus)
2014

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., Perez, E. A., Ciruelos, E., Stearns, V., Bonnefoi, H. R., Martino, S., Geyer, C. E., Pinotti, G., Puglisi, F., Crivellari, D., Ruhstaller, T., Winer, E. P. & 13 others, Rabaglio-Poretti, M., Maibach, R., Ruepp, B., Giobbie-Hurder, A., Price, K. N., Bernhard, J., Luo, W., Ribi, K., Viale, G., Coates, A. S., Gelber, R. D., Goldhirsch, A. & Francis, P. A., jan. 1 2014, In : New England Journal of Medicine. 371, 2, p. 107-118 12 p.

Research output: Article

317 Citations (Scopus)

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial

von Minckwitz, G., Puglisi, F., Cortes, J., Vrdoljak, E., Marschner, N., Zielinski, C., Villanueva, C., Romieu, G., Lang, I., Ciruelos, E., De Laurentiis, M., Veyret, C., de Ducla, S., Freudensprung, U., Srock, S. & Gligorov, J., okt. 1 2014, In : The Lancet Oncology. 15, 11, p. 1269-1278 10 p.

Research output: Article

94 Citations (Scopus)

Bosutinib in combination with the aromatase inhibitor exemestane: A phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer

Moy, B., Neven, P., Lebrun, F., Bellet, M., Xu, B., Sarosiek, T., Chow, L., Goss, P., Zacharchuk, C., Leip, E., Turnbull, K., Bardy-Bouxin, N., Duvillié, L. & Láng, I., 2014, In : Oncologist. 19, 4, p. 346-347 2 p.

Research output: Article

6 Citations (Scopus)

Bosutinib in combination with the aromatase inhibitor letrozole: A phase II trial in postmenopausalwomen evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer

Moy, B., Neven, P., Lebrun, F., Bellet, M., Xu, B., Sarosiek, T., Chow, L., Goss, P., Zacharchuk, C., Leip, E., Turnbull, K., Bardy-Bouxin, N., Duvillié, L. & Láng, I., 2014, In : Oncologist. 19, 4, p. 348-349 2 p.

Research output: Article

12 Citations (Scopus)

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): A randomised trial

Aebi, S., Gelber, S., Anderson, S. J., Láng, I., Robidoux, A., Martín, M., Nortier, J. W. R., Paterson, A. H. G., Rimawi, M. F., Cañada, J. M. B., Thürlimann, B., Murray, E., Mamounas, E. P., Geyer, C. E., Price, K. N., Coates, A. S., Gelber, R. D., Rastogi, P., Wolmark, N. & Wapnir, I. L., febr. 1 2014, In : The Lancet Oncology. 15, 2, p. 156-163 8 p.

Research output: Article

110 Citations (Scopus)

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial

André, F., O'Regan, R., Ozguroglu, M., Toi, M., Xu, B., Jerusalem, G., Masuda, N., Wilks, S., Arena, F., Isaacs, C., Yap, Y. S., Papai, Z., Lang, I., Armstrong, A., Lerzo, G., White, M., Shen, K., Litton, J., Chen, D., Zhang, Y. & 3 others, Ali, S., Taran, T. & Gianni, L., máj. 2014, In : The Lancet Oncology. 15, 6, p. 580-591 12 p.

Research output: Article

285 Citations (Scopus)

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

De Azambuja, E., Holmes, A. P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R. F., Untch, M., Jackisch, C., Lang, I., Smith, I., Boyle, F., Xu, B., Barrios, C. H., Perez, E. A., Azim, H. A., Kim, S. B., Kuemmel, S., Huang, C. S., Vuylsteke, P., Hsieh, R. K. & 7 others, Gorbunova, V., Eniu, A., Dreosti, L., Tavartkiladze, N., Gelber, R. D., Eidtmann, H. & Baselga, J., jan. 1 2014, In : The Lancet Oncology. 15, 10, p. 1137-1146 10 p.

Research output: Article

248 Citations (Scopus)

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

Brodowicz, T., Lang, I., Kahan, Z., Greil, R., Beslija, S., Stemmer, S. M., Kaufman, B., Petruzelka, L., Eniu, A., Anghel, R., Koynov, K., Vrbanec, D., Pienkowski, T., Melichar, B., Spanik, S., Ahlers, S., Messinger, D., Inbar, M. J. & Zielinski, C., nov. 25 2014, In : British journal of cancer. 111, 11, p. 2051-2057 7 p.

Research output: Article

16 Citations (Scopus)

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

Huober, J., Cole, B. F., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D. & Thürlimann, B., jan. 2014, In : Breast Cancer Research and Treatment. 143, 1, p. 159-169 11 p.

Research output: Article

20 Citations (Scopus)

Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: Final results of the retreatment after herceptin adjuvant trial

Láng, I., Bell, R., Feng, F. Y., Lopez, R. I., Jassem, J., Semiglazov, V., Al-Sakaff, N., Heinzmann, D. & Chang, J., febr. 1 2014, In : Clinical Oncology. 26, 2, p. 81-89 9 p.

Research output: Article

17 Citations (Scopus)
2013
3 Citations (Scopus)

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a " standard chemotherapy regimen": The CASA randomized trial

Crivellari, D., Gray, K. P., Dellapasqua, S., Puglisi, F., Ribi, K., Price, K. N., Láng, I., Gianni, L., Spazzapan, S., Pinotti, G., Lüthi, J. M., Gelber, R. D., Regan, M. M., Colleoni, M., Castiglione-Gertsch, M., Maibach, R., Rabaglio, M., Coates, A. S. & Goldhirsch, A., ápr. 2013, In : Breast. 22, 2, p. 130-137 8 p.

Research output: Article

29 Citations (Scopus)

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: The adjuvant lapatinib and/or trastuzumab treatment optimization experience

Metzger-Filho, O., de Azambuja, E., Bradbury, I., Saini, K. S., Bines, J., Simon, S. D., van Dooren, V., Aktan, G., Pritchard, K. I., Wolff, A. C., Smith, I., Jackisch, C., Lang, I., Untch, M., Boyle, F., Xu, B., Baselga, J., Perez, E. A. & Piccart-Gebhart, M., márc. 4 2013, In : Oncologist. 18, 2, p. 134-140 7 p.

Research output: Review article

17 Citations (Scopus)

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

Martin, M., Bonneterre, J., Geyer, C. E., Ito, Y., Ro, J., Lang, I., Kim, S. B., Germa, C., Vermette, J., Wang, K., Wang, K. & Awada, A., dec. 1 2013, In : European Journal of Cancer. 49, 18, p. 3763-3772 10 p.

Research output: Article

84 Citations (Scopus)

Az epeúti carcinomák gyógyszeres kezelé sének lehetõségei. Múlt - Jelen - Jóvo

Gábor, R., Erika, H. & István, L., júl. 24 2013, In : Lege Artis Medicinae. 23, 5-6, p. 255-261 7 p.

Research output: Article

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial

Cunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D., Osborne, S., Andre, N., Waterkamp, D. & Saunders, M. P., okt. 1 2013, In : The Lancet Oncology. 14, 11, p. 1077-1085 9 p.

Research output: Article

334 Citations (Scopus)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: Interim efficacy results of the randomised, Open-label, Non-inferiority, Phase 3 TURANDOT trial

Lang, I., Brodowicz, T., Ryvo, L., Kahan, Z., Greil, R., Beslija, S., Stemmer, S. M., Kaufman, B., Zvirbule, Z., Steger, G. G., Melichar, B., Pienkowski, T., Sirbu, D., Messinger, D. & Zielinski, C., febr. 1 2013, In : The Lancet Oncology. 14, 2, p. 125-133 9 p.

Research output: Article

77 Citations (Scopus)

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study

Rubovszky, G., Láng, I., Ganofszky, E., Horváth, Z., Juhos, É., Nagy, T., Szabó, E., Szentirmay, Z., Budai, B. & Hitre, E., dec. 1 2013, In : European Journal of Cancer. 49, 18, p. 3806-3812 7 p.

Research output: Article

34 Citations (Scopus)
33 Citations (Scopus)